Plaque inhibition assay for drug susceptibility testing of influenza viruses

Antimicrob Agents Chemother. 1980 May;17(5):865-70. doi: 10.1128/AAC.17.5.865.

Abstract

The relative antiviral activities of four drugs against contemporary strains of influenza A and B viruses were determined in Madin-Darby canine kidney cell monolayers with a plaque inhibition assay. This assay proved to be a reliable, rapid method of determining 50% inhibitory concentrations that correlated well with clinically achievable drug levels and the results of clinical trials. Contemporary strains of influenza A viruses (subtypes H1N1, H3N2, HSW1N1) required amantadine hydrochloride and rimantadine hydrochloride 50% inhibitory concentrations in the range of 0.2 to 0.4 microgram/ml, whereas 50% inhibitory concentrations ranged from approximately 50 to 100 micrograms/ml against influenza B viruses. Ribavirin was approximately 10-fold less active than amantadine hydrochloride against influenza A viruses, and the ribavirin 50% inhibitory concentrations against both influenza A and B viruses ranged from 2.6 to 6.8 micrograms/ml. Inosiplex had no antiviral activity in this test system.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amantadine / pharmacology
  • Antiviral Agents / pharmacology*
  • Drug Resistance, Microbial
  • Humans
  • Influenza, Human / microbiology
  • Microbial Sensitivity Tests / methods*
  • Orthomyxoviridae / drug effects*
  • Ribavirin / pharmacology
  • Rimantadine / pharmacology
  • Time Factors
  • Viral Plaque Assay*

Substances

  • Antiviral Agents
  • Rimantadine
  • Ribavirin
  • Amantadine